• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Trends in Microbiology >How academic labs can approach the drug discovery process as a way to synergize with big pharma
【24h】

How academic labs can approach the drug discovery process as a way to synergize with big pharma

机译：学术实验室如何将药物发现过程作为与大型制药公司协同的方法

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

While the pharmaceutical industry is facing highly challenging times, the academic drug discovery sector has the potential to contribute meaningfully to the discovery of novel drug targets and to the development of new mode-of-action therapeutics against a range of diseases, including rare and neglected diseases. Drug discovery is usually a long and very expensive process (taking an average of 10-20 years and more than $1 billion investment) in which new compounds with activity against a specific target are identified, characterized, and developed for clinical applications [1,2]. The first, essential step in the drug discovery pipeline involves the identification and early validation of disease-modifying targets for which pharmacological modulationis predicted to produce a beneficial effect [3]. The drug discovery process is illustrated in Figure 1. Hopefully, the whole process generates clinical drug candidates that are finally evaluated in human clinical trials before being subjected to approvalas a new therapeutic agent(s) for disease treatment.
机译：在制药行业面临严峻挑战的时期，学术药物发现行业有潜力为发现新的药物靶标和开发针对多种疾病（包括罕见和被忽视的疾病）的新型作用模式疗法做出有意义的贡献疾病。药物发现通常是一个漫长且非常昂贵的过程（平均需要10至20年的时间，投资额超过10亿美元），在此过程中，要针对临床目标识别，表征和开发具有新目标的新化合物[1,2] ]。药物发现流程中的第一步，必不可少的步骤是识别和早期验证疾病修饰靶标，并预测其可产生药理作用[3]。药物发现过程如图1所示。希望整个过程产生临床候选药物，这些药物最终将在人类临床试验中进行评估，然后再批准用作疾病治疗的新治疗剂。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号